IRCT20220209053979N12已完成Unknown
Bioequivalence Study of sustained release Diclofenac 100 mg capsule manufactured by Tasinm Pharmaceutical and and Diclofenac 100 mg capsule menufactured by Ratio pharm in 24 Healthy volunteers under fasting condition
Tasnim Pharmaceutical0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Healthy male or female volunteers
- •Body mass index (BMI) between 18 - 30
- •Volunteers who are willing to sign an informed consent form
排除标准
- •History of allergic reaction to memantin or formulation components
- •Taking any type of medicine in the 14 days before the start of the study
- •Participation in any type of clinical study in the last month
研究者
相似试验
已完成
1 期
Bioequivalence of diclofenac sodium retardArthritis, RheumatoidHealthy VolunteersArthritisRheumatic DiseasesJoint DiseasesMusculoskeletal DiseasesConnective Tissue DiseasesAutoimmune DiseasesAutoimmune System DiseasesRheumatoid ArthritisRPCEC00000254Center for Pharmaceutical Research and Development, Havana, Cuba36
招募中
4 期
Comparative study of effectiveness of Diclofenac cream and Plai oil 14% cream for treatment of low back paiow back pain resolvedLow back pain,Topical NSAIDS,Diclofenac cream,Plai oil 14% creamTCTR20140220002Faculty of Medicine ,PS120
已完成
3 期
Effects of Diclofenac on Urethral stricture treatment paiUrethral strictureIRCT20220711055433N1Mashhad University of Medical Sciences40
已完成
3 期
Clinical Trial Assessment of the effect of Diclofenac gel and EMLA ointmentCondition 1: Diclofenac gel on vein puncture pain severity with vein catheter. Condition 2: EMLA ointment on vein puncture pain severity with vein catheter.Other nonsteroidal anti-inflammatory drugsLocal anaestheticsIRCT201008234618N1Sediqeh Khalili (personal)90
进行中（未招募）
不适用
Evaluation of therapeutic equivalence of diclofenac gel 1% formulation compared to Voltaren emulGel 1% gel in subjects with traumatic pathology: a double blind, randomized, phase III multicentre study. - NDEUCTR2010-020521-40-ITEPIFARMA S.R.L.